Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo

Seema Garde, Anil Sheth, Arthur T. Porter, Kenneth J. Pienta

Research output: Contribution to journalArticlepeer-review


Prostatic inhibin peptide (PIP), is a 94 amino acid protein which is secreted by the prostate gland in an androgen‐independent manner. Previously, it has been demonstrated that PIP appears to inhibit follicle‐stimulating‐hormone (FSH) secretion by the pituitary and prostate glands. In vitro, the Dunning R3327 rat prostate cancer cell line MAT‐LyLu (MLL) cells and the human prostate cancer cell line PC‐3, are stimulated to grow in response to exogenous FSH and these effects are blocked by PIP. In vivo, PIP inhibits the growth of the highly metastatic MLL prostate cancer cell line. A comparison of hormone levels in control and PIP‐treated rats demonstrates a significant inhibition of FSH in treated animals. It appears that, in vivo, PIP may inhibit prostate cancer growth by inhibiting FSH. PIP may represent a novel hormonal treatment for prostate cancer. © 1993 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)225-233
Number of pages9
JournalThe Prostate
Issue number3
StatePublished - 1993
Externally publishedYes


  • FSH
  • MLL
  • PC‐3
  • chemotherapeutic drug

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo'. Together they form a unique fingerprint.

Cite this